AcquisitionsMay 11, 2026, 09:26 AM
Aurinia Completes Kezar Life Sciences Acquisition for $6.955/Share
AI Summary
Aurinia Pharmaceuticals Inc. has completed its previously announced acquisition of Kezar Life Sciences, Inc. The tender offer, which expired on May 8, 2026, resulted in approximately 80.24% of Kezar's outstanding shares being tendered at a price of $6.955 in cash plus one contingent value right per share. Following the successful tender offer, the merger was finalized on May 11, 2026, with Kezar becoming a wholly owned subsidiary of Aurinia Pharma U.S., Inc.
Key Highlights
- Aurinia Pharmaceuticals Inc. completed the acquisition of Kezar Life Sciences, Inc.
- The tender offer price was $6.955 in cash per share plus one contingent value right (CVR).
- Approximately 80.24% of Kezar's outstanding shares, totaling 5,927,580, were validly tendered.
- The tender offer and withdrawal rights expired on May 8, 2026.
- The merger was completed on May 11, 2026, making Kezar a wholly owned subsidiary.
- In-the-Money Options were converted into cash (Cash Amount minus exercise price) and one CVR per share.
Price Impact
More from AUPH